Cardiovascular Disease Among Patients With AML and CHIP-Related Mutations

• Main Authors: Abdel-Qadir, H. (Author), Calvillo-Argüelles, O. (Author), Capo-Chichi, J.-M (Author), Carrillo-Estrada, M. (Author), Gupta, V. (Author), Liu, S. (Author), Natarajan, P. (Author), Schimmer, A.D (Author), Schoffel, A. (Author), Schuh, A. (Author), Shlush, L.I (Author), Thavendiranathan, P. (Author), Yee, K. (Author)
• Format: Article
• Language: English
• Published: Elsevier Inc. 2022
• Subjects: acute coronary syndrome; acute myeloid leukemia; adult; age; aged; Article; ASXL1 gene; cardiovascular disease; cardiovascular diseases; cardiovascular mortality; cause of death; clonal hematopoiesis; clonal hematopoiesis of indeterminate potential; cohort analysis; coronary artery recanalization; DNMT3A gene; female; gene; gene mutation; heart failure; hospitalization; human; ischemic stroke; JAK2 gene; major clinical study; male; SF3B1 gene; SRSF2 gene; TET2 gene; TP53 gene; venous thromboembolism
• Online Access: View Fulltext in Publisher

 Background: Clonal hematopoiesis of indeterminate potential (CHIP) is a novel cardiovascular disease (CVD) risk factor in individuals without acute myeloid leukemia (AML). Objectives: The aim of this study was to examine the association between mutations associated with CHIP (CHIP-related mutations) identified in patients at AML diagnosis and the risk for cardiovascular events (CVEs). Methods: This was a retrospective cohort study of 623 patients with AML treated between 2015 and 2018 who underwent DNA analysis. Cause-specific hazard regression models were used to study the associations between pathogenic mutations in common CHIP-related genes (DNMT3A, TET2, ASXL1, JAK2, TP53, SRSF2, and SF3B1) and the rate of CVEs (heart failure hospitalization, acute coronary syndrome, coronary artery revascularization, ischemic stroke, venous thromboembolism, and CVD death) and between CVE development and all-cause mortality. Results: Patients were 64.6 ± 15.3 years of age, 265 (42.5%) were women, and 63% had at least 1 CHIP-related mutation. Those with CHIP-related mutations were older (69.2 ± 12.3 vs 56.6 ± 16.6 years; P < 0.001) and had a greater prevalence of CVD risk factors and CVD history. In adjusted analysis, the presence of any CHIP-related mutation was associated with a higher rate of CVEs (HR: 1.74; 95% CI: 1.03-2.93; P = 0.037) among intensively treated patients (anthracycline based) but not the whole cohort (HR: 1.26; 95% CI: 0.81-1.97; P = 0.31). TP53 (HR: 4.18; 95% CI: 2.07-8.47; P < 0.001) and ASXL1 (HR: 2.37; 95% CI: 1.21-4.63; P = 0.012) mutations were associated with CVEs among intensively treated patients. Interval development of CVEs was associated with all-cause mortality (HR: 1.99; 95% CI: 1.45-2.73; P < 0.001). Conclusions: Among patients with AML treated with intensive chemotherapy, mutations in CHIP-related genes were associated with an increased risk for developing incident CVEs after AML diagnosis. © 2022 The Authors